home / stock / imrx / imrx articles

IMRX Articles, Immuneering Corporation - From 03/14/24

Stock Information
Company Name: Immuneering Corporation
Stock Symbol: IMRX
Market: NASDAQ
Website: immuneering.com
Menu
IMRX IMRX Quote IMRX Short IMRX News IMRX Articles IMRX Message Board
Get IMRX Alerts

News, Short Squeeze, Breakout and More Instantly...
US Stocks Higher; Producer Prices Rise 0.6% In February | Benzinga

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084...
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors | Benzinga

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterati...

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors | Benzinga

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop...

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 | Benzinga

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop...
Immuneering Announces Participation in February Investor Conferences | Benzinga

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop ...

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference | Benzinga

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop ...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Immuneering Corporation (NASDAQ: IMRX) and Encourages Investors to Contact the Firm | Benzinga

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Immuneering Corporation (NASDAQ:IMRX) on beh...
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference | Benzinga

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstra...

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Benzinga

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicine...

Previous 10 Next 10